In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

MuSK antibody positive adults and pediatric gMG patients aged 12 and older. FDA Approves New Treatment for Generalized ...

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...